References

Chemo Secrets From a Breast Cancer Survivor

Breast Cancer Survivors

Get Instant Access

1. Dighiero G, Travade P, Chevret S, Fenaux P, Chastang C, Binet JL. B-cell chronic lymphocytic leukemia: present status and future directions. French Cooperative Group on CLL. Blood 1991;78:1901-1914.

2. Matutes E, Owusu-Ankomah K, Morilla R, et al. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia 1994;8:1640-1645.

3. Zomas AP, Matutes E, Morilla R, Owusu-Ankomah K, Seon BK, Catovsky D. Expression of the immunoglobulin-associated protein B29 in B cell disorders with the monoclonal antibody SN8 (CD79b). Leukemia 1996;10:1966-1970.

4. Ternynck T, Dighiero G, Follezou J, Binet JL. Comparison of normal and CLL lymphocyte surface Ig determinants using peroxidase-labeled antibodies. I. Detection and quantitation of light chain determinants. Blood 1974;43:789-795.

5. Conley CL, Misiti J, Laster AJ. Genetic factors predisposing to chronic lymphocytic leukemia and to autoimmune disease. Medicine 1980;59:323-334.

6. Linet MS, Van Natta ML, Brookmeyer R, et al. Familial cancer history and chronic lymphocytic leukemia. A case-control study. Am J Epidemiol 1989;130:655-664.

7. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood 1975;46:219-234.

8. Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981;48:198-206.

9. French Cooperative Group on Chronic Lymphocytic Leukemia. Effects of chlorambucil and therapeutic decision in initial forms of chronic lymphocytic leukemia (stage A): results of a randomized clinical trial on 612 patients. Blood 1990;75:1414-1421.

10. Dighiero G, Maloum K, Desablens B, et al. Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia. N Eng J Med 1998;338:1506-1514.

11. Catovsky D, Fooks J, Richards S. The UK Medical Research Council CLL trials 1 and 2. Nouv Rev Fr Hematol 1988;30:423-427.

12. Shustik C, Mick R, Silver R, Sawitsky A, Rai K, Shapiro L. Treatment of early chronic lymphocytic leukemia: intermittent chlorambucil versus observation. Hematol Oncol 1988;6:7-12.

13. Spanish Cooperative Group Pethema. Treatment of chronic lymphocytic leukemia: a preliminary report of Spanish (Pethema) trials. Leuk Lymphoma 1991;5:89-91.

14. CLL Trialists' Collaborative Group. Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analy-sis of the randomized trials. CLL Trialists' Collaborative Group. J Natl Cancer Inst 1999;91:861-868.

15. Jaksic B, Brugiatelli M. High dose continuous chlorambucil vs intermittent chlorambucil plus prednisone for treatment of B-CLL—IGCI CLL-01 trial. Nouv Rev Fr Hematol 1988;30:437-442.

16. French Cooperative Group on Chronic Lymphocytic Leukaemia. Natural history of stage A chronic lymphocytic leukaemia untreated patients. Br J Haematol 1990;76:45-57.

17. Montserrat E, Vinolas N, Reverter JC, Rozman C. Natural history of chronic lymphocytic leukemia: on the progression and prognosis of early clinical stages. Nouv Rev Fr Hematol 1988;30:359-361.

18. Keating MJ, Lerner S, Kantarjian H, Freireich EJ, O'Brien S. The serum beta2-microglobulin (beta2M) level is more powerful than stage in predicting response and survival in chronic lymphocytic leukemia (CLL). Blood 1998;86:606a.

19. Sarfati M, Bron D, Lagneaux L, Fonteyn C, Frost H, Delespesse G. Elevation of IgE-binding factors in serum of patients with B cell-derived chronic lymphocytic leukemia. Blood 1988; 71:94-98.

20. Léotard S. Etude de la valeur pronostique du CD23 soluble dans la leucémie Lymphnoeud Chronique chez des patients en stade A, non traités. Comparaison avec la béta2-microglobuline, l'albumine et la LDH. These pour le diplúme d'état de Docteur en Pharmacie. Université de Paris Sud, 1998.

21. Hallek M, Langenmayer I, Nerl C, et al. Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early , nonsmoldering chronic lymphocytic leukemia. Blood 1999;93(5): 1732-1737.

22. Dohner H, Stilgebauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000;343(26):1910-1916.

23. Schroeder HW, Jr., Dighiero G. The pathogenesis of chronic lymphocytic leukemia: analysis of the antibody repertoire. Immunol Today 1994;15:288-294.

24. Damle RN, Wasil T, Fais F, et al. Immunoglobulin V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999;94:1840-1848.

25. Hamblin TJ, Davis Z, Oscier DG, Stevenson FK. Unmutated immunoglobulin VH genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999;94:1848-1855.

26. Maloum K, Pritsch O, Magnac C, et al. Expression of unmutated VH genes is a detrimental prognostic factor in chronic lymphocytic leukemia. Blood, 2000;96:377-379.

27. Klein U, Tu Y, Stolovitzky GA, et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med 2001;194:1625-1638.

28. Rosenwald A, Alizadeh AA, Widhopf G, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 2001;194:1639-1647.

29. French Cooperative Group on Chronic Lymphocytic Leukemia. A randomized clinical trial of chlorambucil versus COP in stage B chronic lymphocytic leukemia. Blood 1990;75:1422-1425.

30. Catovsky D, Hamblin T, Richards S. Preliminary results of UK MRC trial in chronic lymphocytic leukemia-CLL3. In: Proceedings of the 27th Congress of the International Society of Haematology (ISH-EHA). Br J Haematol 1998;102:278, abstract O-114.

31. Montserrat E, Alcala A, Parody R, et al. Treatment of chronic lymphocytic leukemia in advanced stages. A randomized trial comparing chlorambucil plus prednisone versus cyclophosphamide, vincristine, and pred-nisone. Cancer 1985;56:2369-2375.

32. Raphael B, Andersen JW, Silber R, et al. Comparison of chlorambucil and prednisone versus cyclophosphamide, vincristine, and prednisone as initial treatment for chronic lymphocytic leukemia: long-term follow-up of an Eastern Cooperative Oncology Group randomized clinical trial. J Clin Oncol 1991;9:770-776.

33. Hester JP, Gehan EA. Cytoxan, adriamycin, prednisone (CAP) chemotherapy for chronic lymphocytic leukemia (abstract). Proc Am Soc Clin Oncol 1978;19:214.

34. Keating MJ, Scouros M, Murphy S, Kantarjian H, Hester J, McCredie KB, Hersh EM, Freireich EJ. Multiple agent chemotherapy (POACH) in previously treated and untreated patients with chronic lymphocytic leukemia. Leukemia 1988;2:157-164.

35. Hansen MM, Andersen E, Birgens H, Christensen BE, Christensen TG, Geisler C. CHOP versus chlorambucil + prednisolone in chronic lymphocytic leukemia. Leuk Lymphoma 1991;(Suppl 4):97-100.

36. Kimby E, Mellstedt H. Chlorambucil/prednisolone versus CHOP in symtomatic chronic lymphocytic leukemia of B-cell type. Leuk Lymphoma 1991;(suppl 4):93-96.

37. Jaksic B, Brugiatelli M, Krc I, et al. High dose chlorambucil versus Binet's modified cyclophosphamide, doxorubicin, vincristine, and prednisone regimen in the treatment of patients with advanced B-cell chronic lymphocytic leukemia. Results of an international multicenter randomized trial. International Society for Chemo-Immunotherapy, Vienna. Cancer 1997;79:2107-2114.

38. French Cooperative Group on Chronic Lymphocytic Leukaemia. Effectiveness of "CHOP" regimen in advanced untreated chronic lymphocytic leukaemia. Lancet 1986;1:1346-1349.

39. French Cooperative Group on Chronic Lymphocytic Leukaemia. Long-term results of the CHOP regimen in stage C chronic lymphocytic leukaemia. Br J Haematol 1989;73:334-340.

40. French Cooperative Group on CLL. Is the CHOP regimen a good treatment for advanced CLL? Results from two randomized clinical trials. French Cooperative Group on Chronic Lymphocytic Leukemia. Leuk Lymphoma 1994;13:449-456.

41. Leporrier M, Chevret S, Cazin B, et al. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood 2001;98:2319-2325.

42. Binet JL, Leporrier M, Dighiero G, et al. A clinical staging system for chronic lymphocytic leukemia. Prognostic significance. Cancer 1977;40:855-864.

43. Kempin S, Lee BJd, Thaler HT, et al. Combination chemotherapy of advanced chronic lymphocytic leukemia: the M-2 protocol (vincristine, BCNU, cyclophosphamide, melphalan, and prednisone). Blood 1982;60:1110-1121.

44. Grever MR, Kopecky KJ, Coltman CA, et al. Fludarabine monophosphate: a potentially useful agent in chronic lymphocytic leukemia. Nouv Rev Fr Hematol 1988;30:457-459.

45. Piro LD, Carrera CJ, Beutler E, Carson DA. 2-Chlorodeoxyadenosine: an effective new agent for the treatment of chronic lymphocytic leukemia. Blood 1988;72:1069-1073.

46. Keating MJ, Kantarjian H, Talpaz M, et al. Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood 1989;74:19-25.

47. O'Brien S, Kantarjian H, Beran M, et al. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment [see comments]. Blood 1993;82:1695-1700.

48. Keating MJ, O'Brien S, Lerner S, et al. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood 1998;92:1165-1171.

49. Byrd JC, Rai KR, Sausville EA, Grever MR. Old and new therapies in chronic lymphocytic leukemia: now is the time for a reassessment of therapeutic goals. Semin Oncol 1998;25:65-74.

50. O'Brien SM, Kantarjian HM, Cortes J, et al . Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol. 2001;19:1414-1420.

51. Hallek M, Schmitt B, Wilhelm M, et al. Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II. Br J Haematol. 2001;114(2):342-348.

52. Cazin B, Maloum K, Divine M, et al.. Oral fludarabine and cyclophosphamide in previously CLL Data on 59 patients (abstract). Blood 2001;98 (Suppl 1):3214a.

53. Frewin R, Turner D, Tighe M, et al. Combination therapy with fludarabine and cyclophosphamide as salvage treatment in lymphoproliferative disorders. Br J Haematol. 1999;104:612-613.

54. Flinn IW, Byrd JC, Morrison C, et al. Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies. Blood 2000;96:71-75.

55. Saven A, Piro LD. 2-Chlorodeoxyadenosine: a potent antimetabolite with major activity in the treatment of indolent lymphoproliferative disorders. Hematol Cell Ther 1996;38:S93-101.

56. Saven A, Lemon RH, Kosty M, Beutler E, Piro LD. 2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia. J Clin Oncol 1995;13:570-574.

57. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996;87:4990-4997.

58. The French Cooperative Group on CLL, Johnson S, Smith AG, Loffler H, et al. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. Lancet 1996; 347:1432-1438.

59. Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia, N Engl J Med 2000;343:1750-1757.

60. Spriano M, Chiurazzi F, Liso V, Mazza P, Molica S, Gobbi M. Multicentre prospective randomized trial of fludarabine versu chlorambucil and prednisone in previously untreated patients with active B-CLL (abstract). In: Proceedings of the International Workshop on CLL. Paris, October 1999, p. 86.

61. Jaksic B, Delmer A, Brugiatelli M, et al. Interim analysis of a randomised EORTC study comparing high dose chlorambucil (HD-CLB) vs fludarabine (FAMP) in untreated B-cell chronic lymphocytic leukaemia (CLL). Hematol Cell Ther 1997; 39:S87.

62. Robak T, Blonski JZ, Kasznicki M, et al. Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial. Blood 2000;96:2723-2729.

63. Riechmann L, Clark M, Waldmann H, Winter G. Reshaping human antibodies for therapy. Nature 1988;332:323-327.

64. Flynn JM, Byrd JC. Campath-1H monoclonal antibody therapy. Cur Opin Immunol 2000;12:574-581.

65. Osterborg A, Fassas AS, Anagnostopoulos A, et al. Humanized CD52 monoclonal antibody Campath-1H as firstline treatment in chronic lymphocytic leukaemia. Br J Haematol 1996;93:151-153.

66. Osterborg A, Dyer MJ, Bunjes D, et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. J Clin Oncol 1997;15:1567-1574.

67. Dyer MJ, Kelsey SM, Mackay HJ, et al. In vivo "purging" of residual disease in CLL with Campath-IH. Br J Haematol 1997;97:669-672.

68. Gilleece MH, Dexter TM. Effect of campath-lH antibody on human hematopoietic progenitors in vitro. Blood 1993;82:807-812.

69. Bowen AL, Zomas A, Emmett E, Matutes E, Dyer MJ, Catovsky D. Subcutaneous Campath-lH in fludarabine-resistant/relapsed chronic lymphocytic leukemia. Br J Haematol 1997;96:617-619.

70. Grillo-Lopez AJ, Hedrick E, Rashford M, Benyunes M. Rituximab: ongoing and future clinical development (review). Semin Oncol 2002;29 (suppl 2):105-112.

71. O'Brien SM, Kantarjian H, Thomas DA, et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 2001;19:2165-2170.

72. Byrd JC, Murphy T, Howard RS, et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 2001;19:2153-2164.

73. Kaminski MS, Estes J, Zasadny KR, et al. Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 2000;96:1259-1266.

74. Rai KR, Dohner H, Keating MJ, Montserrat E. Chronic lymphocytic leukemia: case-based session. Hematology (Am Soc Hematol Educ Program) 2001;Jan:140-156.

75. Michallet M, Corront B, Hollard D, et al. Allogeneic bone marrow transplantation in chronic lymphocytic leukemia: 17 cases. Report from the EBMTG, Bone Marrow Transplant 1991;7:275-279.

76. Rabinowe SN, Soiffer RJ, Gribben JG, et al. Autologous and allogeneic bone marrow transplantation for poor prognosis patients with B-cell chronic lymphocytic leukemia. Blood. 1993;82:1366-1376.

77. Khouri IF, Keating MJ, Vriesendorp HM. Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: preliminary results. J Clin Oncol 1994;12:748-758.

78. Michallet M, Archimbaud E, Bandini G, et al. HLA-identical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia. European Group for Blood and Marrow Transplantation and the International Bone Marrow Transplant Registry. Ann Intern Med 1996;124:311-315.

79. Michallet M, Thiebaut A, Dreger P, et al. Peripheral blood stem cell (PBSC) mobilization and transplantation after fludarabine therapy in chronic lymphocytic leukaemia (CLL): a report of the European Blood and Marrow Transplantation (EBMT) CLL subcommittee on behalf of the EBMT Chronic Leukaemias Working Party (CLWP). Br J Haematol 2000;108:595-601.

80. Dreger P, von Neuhoff N, Kuse R, et al. Early stem cell transplantation for chronic lymphocytic leukaemia: a chance for cure? Br J Cancer 1998;77:2291-2297.

81. Provan D, Bartlett-Pandite L, Zwicky C, et al. Eradication of polymerase chain reaction-detectable chronic lymphocytic leukemia cells is associated with improved outcome after bone marrow tranplantation. Blood 1996; 88:2228-2235.

82. Sutton L, Maloum K, Gonzalez H, et al. Autologous hematopoietic stem cell transplantation as salvage treatment for advanced B cell chronic lymphocytic leukemia. Leukemia 1998;12:1699-1707.

83. Giralt S, Estey E, Albitar M, et al. Engraftment of allogenic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft versus leukemia without myeloablative therapy. Blood 1997;89:4531-4536.

84. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation xith lethal cytoreduction for the treatment of malignant and non malignant hematologic diseases. Blood 1998;91:756-763.

85. Khouri IF, Keating M, Korbling M, Pet al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998;16:2817-2824.

86. Lawrence JH, Low-Beer BVA, Carpender JWJ. Chronic lymphatic leukemia: study of 100 patients with radioactive phosphorus. JAMA 1949;140:585.

87. Johnson RE: Total body irradiation of chronic lymphocytic leukemia. Cancer 1976;37:2691.

88. Chanana AD, Cronkite EP, Rai KR: The role of extracorporeal irradiation of blood in the treatment of leukemia. Int J Radiat Oncol Biol Phys 1976;1:539-548.

89. Richards F, Spurr CL, Ferree C, Blake DD, Raben M: The control of chronic lymphocytic leukemia with mediastinal irradiation. Am J Med 1978;64:947-954.

90. Ferrant A, Michaux JL, Sokal G. Splenectomy in advanced chronic lymphocytic leukemia. Cancer 1986;58: 2130-2696.

91. Stein RS, Weikert D, Reynols V Greer JP, Flexner JM: Splenectomy for end-stage chronic lymphocytic leukemia. Cancer 1987;59:1815-1818.

92. Delpero JR, Mouvenaeghel G, Gastaut JA, et al. Splenectomy for hypersplenism in chronic lymphocytic leukemia and malignant non-Hodgkin's lymphoma. Br J Surg 1990;77:443-449.

93. Hsu FJ, Caspar CB, Czerwinski D, et al. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma—long-term results of a clinical trial. Blood 1997;89:3129-3135.

94. Kipps TJ. Future strategies toward the cure of indolent B-cell malignancies. Molecular genetic approaches. Semin Hematol 1999;36:3-8.

95. Cheson BD. Emerging therapies and future directions in chronic lymphocytic leukaemia-chemotherapy. Hematol Cell Ther 2000;42(1):41-47.

96. Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia. Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized control trial. N Engl J Med 1988;319:902-907.

97. Dighiero G, Binet JL. When and how to treat chronic lymphocytic leukemia. N Engl J Med 2000;343:1799-1802.

98. Hansen MM. Chronic lymphocytic leukaemia. Clinical studies based on 189 cases followed for a long time. Scand J Haematol 1973;(suppl 18):3-286.

99. Lim LC, Koh LP, Tan P. Fatal cytokine release syndrome with chimeric anti-CD20 monoclonal antibody rituximab in a 71-year-old patient with chronic lymphocytic leukemia. J Clin Oncol 1999;17:1962-1963.

100. Yang H, Rosove MH, Figlin RA. Tumor lysis syndrome occurring after the administration of rituximab in lymphoproliferative disorders: high-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Am J Hematol 1999;62:247-250.

101. Winkler U, Jensen M, Manzke O, Schulz H, Diehl B, Engert A. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood 1999;94:2217-2224.

Was this article helpful?

0 0
10 Ways To Fight Off Cancer

10 Ways To Fight Off Cancer

Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.

Get My Free Ebook


Post a comment